Different demographic variables, ICU treatment, and outcome parameters were evaluated.
Shock was defined as norepinephrine dose >0.1 μg/kg/min and serum lactate level >2 mmol/l at the start of methylene blue administration. We performed a retrospective cohort study of patients in shock treated with methylene blue. Therefore, we investigated the hemodynamic and ICU outcome parameters of three different dosing strategies for methylene blue. However, the optimal dosing strategy remains elusive. In the past, studies have found that the NO-pathway antagonist methylene blue improves hemodynamics. Shock increases mortality in the critically ill and the mainstay of therapy is the administration of vasopressor agents to achieve hemodynamic targets.
0 kommentar(er)
